News
OLMA
11.36
+1.43%
0.16
Weekly Report: what happened at OLMA last week (0318-0322)?
Weekly Report · 3d ago
5 Stocks that Analysts Love in March 2024
TipRanks · 03/18 12:35
Weekly Report: what happened at OLMA last week (0311-0315)?
Weekly Report · 03/18 09:10
3 Best Stocks to Buy Now, 3/13/2024, According to Top Analysts 
TipRanks · 03/13 06:57
Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment
TipRanks · 03/12 13:45
Olema Pharmaceuticals Price Target Maintained With a $21.00/Share by Oppenheimer
Dow Jones · 03/12 12:28
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target
Benzinga · 03/12 12:18
Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
TipRanks · 03/12 12:05
Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity
TipRanks · 03/12 12:05
Olema Pharmaceuticals Price Target Cut to $25.00/Share From $28.00 by HC Wainwright & Co.
Dow Jones · 03/12 10:49
Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/12 10:49
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25
Benzinga · 03/12 10:39
Optimistic Outlook on Olema Pharmaceuticals: A Comprehensive Analysis of Palazestrant’s Clinical Advancements and Future Potential
TipRanks · 03/12 10:26
Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ Palazestrant
TipRanks · 03/12 00:25
Olema Pharmaceuticals GAAP EPS of -$0.49
Olema Pharmaceuticals, Inc. Reports Q4 GAAP EPS of -$0.49. Research and development expenses were $25.9 million for the quarter and year ended December 31, 2023. Cash, cash equivalents and marketable securities were $261.8 million.
Seeking Alpha · 03/11 20:54
Olema Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Olema Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 49 cents per share. The mean expectation of analysts was for a loss of 48 cents. Reported revenue was zero; analysts expected zero; shares had fallen by 7.3% this quarter.
Reuters · 03/11 20:28
Olema Pharmaceuticals Q4 EPS $(0.49) Misses $(0.48) Estimate
Benzinga · 03/11 20:04
Press Release: Olema Oncology Reports Fourth -2-
The results presented in this press release include both GAAP information and non-GAAP information. Olema uses these financial measures to evaluate its ongoing operations and for internal planning and forecasting purposes. This press release includes forward-looking statements. These statements are subject to risks and uncertainties.
Dow Jones · 03/11 20:03
*Olema Pharmaceuticals 4Q Loss/Shr 49c >OLMA
Dow Jones · 03/11 20:03
Weekly Report: what happened at OLMA last week (0304-0308)?
Weekly Report · 03/11 09:10
More
Webull provides a variety of real-time OLMA stock news. You can receive the latest news about Olema Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.